3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Lymphoma
4
Neoplasm Metastasis
3
Multiple Myeloma
3
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Breast Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Melanoma
1
Malignant Solid Neoplasm
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lung Neoplasms
1
Hematologic Neoplasms
1
HER2 Positive Breast Cancer
1
Glioma
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Disease Progression
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
ruxolitinib
13
Cyclophosphamide
5
Tacrolimus
4
Stem Cell Transplantation
4
Specimen Handling
4
fludarabine phosphate
3
Whole-Body Irradiation
3
Peripheral Blood Stem Cell Transplantation
3
Mycophenolic Acid
3
Cyclosporine
3
fludarabine
2
fedratinib
2
Sirolimus
2
Injections
2
Busulfan
2
Blood Component Removal
2
Biopsy
2
Azacitidine
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
venetoclax
1
veliparib
1
umbralisib
1
thymoglobulin
1
selinexor
1
reparixin
1
piperine
1
pevonedistat
1
pegylated granulocyte colony-stimulating factor
1
navitoclax
1
luspatercept
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Primary Myelofibrosis
×
copanlisib
×
90 days
×
Clear all
No trials found.